Birgitte Smith‐Sørensen

2.9k citations

25 papers · 2.4k indexed · 2 hit papers · h-index 17

Oncology top 2%
Molecular Biology top 5%
Cancer Research top 2%
Pulmonary and Respiratory Medicine top 10%
Genetics top 10%

Co-authors: Eivind Hovig Anne‐Lise Børresen Stephanie Geisler Hilde Johnsen Turid Aas Jan Erik Varhaug Lars A. Akslen Per Eystein Lønning
Topics: Cancer-related Molecular Pathways (12 papers)Cancer Genomics and Diagnostics (7 papers)Epigenetics and DNA Methylation (5 papers)
Cited by: Oncology Cancer Research Biotechnology
Journals: Proceedings of the National Academy of Sciences Nature Medicine Journal of Clinical Oncology
Partner nations: Norway United States Switzerland

In The Last Decade

Birgitte Smith‐Sørensen

25 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Database of p53 gene somatic mutations in human tumors and cell lines.

1994 727 citations Eivind Hovig, Birgitte Smith‐Sørensen et al. PubMed profile →
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1996 608 citations Turid Aas, Anne‐Lise Børresen et al. Nature Medicine profile →

Peers

Countries citing papers authored by Birgitte Smith‐Sørensen

Since Specialization

Citations

This map shows the geographic impact of Birgitte Smith‐Sørensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgitte Smith‐Sørensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgitte Smith‐Sørensen more than expected).

Fields of papers citing papers by Birgitte Smith‐Sørensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgitte Smith‐Sørensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgitte Smith‐Sørensen. The network helps show where Birgitte Smith‐Sørensen may publish in the future.

Co-authorship network of co-authors of Birgitte Smith‐Sørensen

This figure shows the co-authorship network connecting the top 25 collaborators of Birgitte Smith‐Sørensen. A scholar is included among the top collaborators of Birgitte Smith‐Sørensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgitte Smith‐Sørensen. Birgitte Smith‐Sørensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Frequent Promoter Hypermethylation of the O ⁶ - Methylguanine-DNA Methyltransferase (MGMT) Gene in Testicular Cancer 2005 ·The Journal of Urology ·Birgitte Smith‐Sørensen,Guro E. Lind,Rolf I. Skotheim,Sophie D. Fosså,Øystein Fodstad,Anna E. Stenwig,Kjetill S. Jakobsen,Ragnhild A. Lothe	8
2	Interferon-γ suppresses S100A4 transcription independently of apoptosis or cell cycle arrest 2003 ·British Journal of Cancer ·Karin Andersen,Birgitte Smith‐Sørensen,Kjetil Boye,Eivind Hovig,Ola Myklebost,Øystein Fodstad,Gunhild M. Mælandsmo	17
3	Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance 2003 ·BMC Genomics ·Vigdis Nygaard,Anders Løland,Marit Holden,Mette Langaas,Håvard Rue,Fang Liu,Ola Myklebost,Øystein Fodstad,Eivind Hovig,Birgitte Smith‐Sørensen	63
4	Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer 2002 ·Oncogene ·Birgitte Smith‐Sørensen,Guro E. Lind,Rolf I. Skotheim,Sophie D. Fosså,Øystein Fodstad,AE Stenwig,Kjetill S. Jakobsen,Ragnhild A. Lothe	61
5	p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy 2000 ·Breast Cancer Research ·Stephanie Geisler,Birgitte Smith‐Sørensen,Daniel Betticher,(unknown),(unknown),Андреас Каппелер,Matthias Gugger,Per Eystein Lønning,(unknown)	1
6	Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status 1998 ·British Journal of Cancer ·Birgitte Smith‐Sørensen,J. Kærn,Ruth Holm,Anne Dørum,Claes G. Tropé,(unknown)	39
7	Detection of Mutations by Single‐Strand Conformation Polymorphism (SSCP) Analysis and SSCP‐Hybrid Methods 1997 ·Current Protocols in Human Genetics ·William Warren,Eivind Hovig,Birgitte Smith‐Sørensen,Anne‐Lise Børresen,Frank K. Fujimura,Qiang Liu,Jinong Feng,Steve S. Sommer	10
8	CDKN2A (p16INK4A) somatic and germline mutations 1996 ·Human Mutation ·Birgitte Smith‐Sørensen,Eivind Hovig	77
9	Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsbreakdown → 1996 ·Nature Medicine ·Turid Aas,Anne‐Lise Børresen,Stephanie Geisler,Birgitte Smith‐Sørensen,Hilde Johnsen,Jan Erik Varhaug,Lars A. Akslen,Per Eystein Lønning	608
10	CDKN2A (p16INK4A) somatic and germline mutations 1996 ·Human Mutation ·Birgitte Smith‐Sørensen,Eivind Hovig	6
11	Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection 1995 ·Human Mutation ·Michael Krawczak,Birgitte Smith‐Sørensen,Jörg Schmidtke,Vijay V. Kakkar,D.N. Cooper,Eivind Hovig	48
12	Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. 1994 ·Journal of Clinical Oncology ·(unknown),Birgitte Smith‐Sørensen,Stephen Friend,(unknown),(unknown),Yu-Xin Yan,Carolyn Russo,Junko Sato,(unknown),J. Miser	145
13	Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE) 1993 ·Human Mutation ·Birgitte Smith‐Sørensen,Mark C. Gebhardt,Peter Kloen,(unknown),Fernando Aguilar,P Cerutti,Anne‐Lise Børresen	33
14	No alterations in exon 21 of the RBI gene in sarcomas and carcinomas of the breast, colon, and lung 1992 ·Genes Chromosomes and Cancer ·Eivind Hovig,Birgitte Smith‐Sørensen,Mark C. Gebhardt,David Ryberg,Ragnhild A. Lothe,Anne‐Lise Børresen	8
15	Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE) 1992 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Birgitte Smith‐Sørensen,Eivind Hovig,Björn Andersson,Anne‐Lise Børresen	17
16	Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma 1992 ·International Journal of Radiation OncologyBiologyPhysics ·James McIntyre,Mark C. Gebhardt,Birgitte Smith‐Sørensen,(unknown),David Malkin,Stephen Friend	1
17	Screening for germ line TP53 mutations in breast cancer patients. 1992 ·PubMed ·A L Børresen,Tone Ikdahl Andersen,Judy E. Garber,(unknown),Steinunn Thorlacius,Jórunn E. Eyfjörd,Lars Ottestad,Birgitte Smith‐Sørensen,Eivind Hovig,David Malkin	143
18	Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection 1991 ·Mutation Research Letters ·Eivind Hovig,Birgitte Smith‐Sørensen,Anton Brögger,Anne‐Lise Børresen	107
19	Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. 1991 ·Proceedings of the National Academy of Sciences ·A L Børresen,Eivind Hovig,Birgitte Smith‐Sørensen,David Malkin,(unknown),T I Andersen,J. M. Nesland,K. J. Isselbacher,Stephen Friend	157
20	Screening for base mutations in the PAH and HPRT loci using the polymerase chain reaction (PCR) in combination with denaturing gradient gel electrophoresis (DGGE). 1990 ·PubMed ·A L Børresen,Eivind Hovig,Birgitte Smith‐Sørensen,Harry Vrieling,Jaran Apold,Anton Brögger	2

About Birgitte Smith‐Sørensen

Birgitte Smith‐Sørensen is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 25 papers that have together received 2.4k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (12 papers), Cancer Genomics and Diagnostics (7 papers) and Epigenetics and DNA Methylation (5 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (674 citations) and Biotechnology (236 citations). Birgitte Smith‐Sørensen has collaborated with scholars based in Norway, United States and Switzerland. Frequent co-authors include Eivind Hovig, Anne‐Lise Børresen, Stephanie Geisler, Hilde Johnsen, Turid Aas, Jan Erik Varhaug, Lars A. Akslen, Per Eystein Lønning, C C Harris and Thierry Soussi. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact